Delivery Order SPE2DB22D1103-SPE2DB24FTQD6

Award Date 8/14/24
Potential Completion Date 8/15/24
Potential Value $1.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Defense Logistics Agency (DLA) awarded a $9,525.39 firm-fixed-price delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 0.25 mg/0.5 mL WEGOVY pens. This order was placed under an Indefinite Delivery Contract (IDC) valued up to $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which provides a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract...
The Defense Logistics Agency (DLA) awarded a $1,645.62 firm fixed-price delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 1.7 MG/0.75 ML PEN 0.75ML. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 2.4 MG/0.75 ML PEN 0.75ML. The $4,123.94 firm fixed-price contract has an ultimate completion date of April 2, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 2.4 MG/0.75 ML PEN 0.75ML. The contract, valued at $3,587.90, has an ultimate completion date of October 30, 2024. This order is part of Amerisourcebergen's $999,999,999 Indefinite Delivery Contract with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract valued at $3,324.85 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 2.4 MG/0.75 ML PEN 0.75ML medication. The contract has a period of performance through May 14, 2025 and is not set-aside. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive global...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $3,460.71 firm-fixed-price delivery order to Amerisourcebergen Drug Corp's Corporate Office Division for the supply of WEGOVY 0.25 MG/0.5 ML PEN 0.5ML. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 with DLA Troop Support Medical, which serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical and medical supplies to support...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distribution company AmerisourceBergen Corporation. The $3,291.24 contract is for the supply of WEGOVY 2.4 mg/0.75 mL pens to support military treatment programs and facilities. This delivery order is part of a larger indefinite delivery contract (IDC) held by AmerisourceBergen Drug Corp with DLA, valued up to $999,999,999.00 through...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract (SPE2DB22D2007|SPE2DB24FJ1MD) worth $1,257.04 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of the pharmaceutical product WEGOVY 2.4 MG/0.75 ML PEN 0.75ML. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp with a potential value of $999,999,999.00 and a performance period through...
The Defense Logistics Agency (DLA) has awarded a delivery order contract to Amerisourcebergen Drug Corp for the supply of WEGOVY 0.25 MG/0.5 ML PEN 0.5ML pharmaceutical products. The contract, valued at $22,044.67, has a firm fixed price and an ultimate completion date of September 17, 2024. Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is the prime contractor for this contract, which is not designated as a set-aside. This delivery order contract is part of a larger Indefinite...
The Defense Logistics Agency (DLA) awarded a $1,979.10 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 1.7 MG/0.75 ML PEN 0.75ML. This contract has an ultimate completion date of September 23, 2024. Amerisourcebergen, through its Corporate Office division, has been awarded numerous federal contracts by various defense and civilian agencies to provide a wide range of pharmaceutical products and medical...
  • SPE2DB22D1103
    Indefinite Delivery Contract
  • SPE2DB22D1103-SPE2DB24FTQD6
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a $1,081.52 firm fixed price delivery order contract to AmerisourceBergen Drug Corp's Corporate Office division, a major pharmaceutical distributor, for the supply of 4565453597 WEGOVY 2.4 MG/0.75 ML PEN 0.75ML. This order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, that enables the agency to efficiently procure a comprehensive range of medical commodities, including pharmaceuticals, to support military treatment programs and facilities worldwide. The contract does not have a set-aside designation and is scheduled for completion by August 15, 2024.

Generated 11/13/24, 9:11 AM